Cost-effectiveness analysis based on two models of sacituzumab tirumotecan versus platinum-based chemotherapy as second-line treatment in EGFR-mutant non-small-cell lung cancer.

Abstract excerpt

Background: For patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC) who progress after first-line therapy, effective subsequent options are urgently needed. From the perspective of China's healthcare system, this study evaluated the cost-effectiveness of sacituzumab tirumotecan (sac-TMT) versus conventional platinum-based chemotherapy, using both a partitioned survival model (PSM) and a Markov...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antineoplastic Agents
• Share to Carcinoma, Non-Small-Cell Lung